Nasus Pharma (NSRX)
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It of...
- Open
- 4.037
- High
- 4.037
- Low
- 3.795
- Prev. Close
- 3.825
- Volume
- 1.16K
- Turnover
- 4.42K
- Avg Price
- 3.800
- Bid/Ask Ratio
- 33.33%
- Amplitude
- 6.33%
- 52wk High
- 9.500
- Volume Ratio
- 0.12
- Turnover Ratio
- 0.02%
Nasus Pharma Analyst Rating
View moreForecast & Rating
Aug 21, 2026Price forecast
$19.67418.23%
Forecast & RatingBuy
2analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Aug 19 at 01:47 PM
Nasus Pharma Names Interim CFO as Longtime Finance Chief Resigns
- PUBT · Aug 19 at 11:00 AM
Nasus Pharma CFO Eyal Rubin to exit; finance director Oren Elmaliach named interim CFO
- PUBT · Aug 17 at 12:14 PM
Nasus Pharma H1 FY26 net loss widens to $5.94 million
- StockTitan · Aug 17 at 04:14 AM
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update | NSRX Stock News
- PUBT · Jul 31 at 08:26 PM
Nasus Pharma CEO and Director Brendan O’Grady files initial beneficial ownership statement
